People Background Check
Find People:

Daniel M Fass, Age 55171 Swanton St UNIT 35, Winchester, MA 01890

Get Report
Related to:
Dorothy A Srnka 88 Caitlin Fass

Daniel Fass Phones & Addresses

171 Swanton St UNIT 35, Winchester, MA 01890

3234 11Th Ave, Portland, OR 97201

2130 Massachusetts Ave, Cambridge, MA 02140

Coraopolis, PA

Marlboro, NJ

Pittsburgh, PA

Mentions for Daniel M Fass

Career records & work history

Medicine Doctors

Daniel E. Fass

Specialties:
Radiation Oncology
Work:
WESTMED Medical GroupWest Medical Group Radiation Oncology
1 Theall Rd STE 107, Rye, NY 10580
(914) 848-8950 (phone) (914) 848-8951 (fax)
Site
Education:
Medical School
Howard University College of Medicine
Graduated: 1983
Languages:
English, Spanish
Description:
Dr. Fass graduated from the Howard University College of Medicine in 1983. He works in Rye, NY and specializes in Radiation Oncology.
Daniel Fass Photo 1

Daniel Eric Fass

Specialties:
Nuclear Medicine
Radiology
Radiation Oncology
Diagnostic Radiology
Therapeutic Radiology
Radium Therapy
Medical Oncology
Education:
Howard University(1983)

Publications & IP owners

Us Patents

Compositions Of Modulators Of The Wnt/B-Catenin Pathway And An N-Cinnamyl-N'benzhydryl Piperazine And Their Use In Treating Neoplastic Conditions Including Malignant Melanoma

US Patent:
2011020, Aug 18, 2011
Filed:
Apr 7, 2009
Appl. No.:
12/936695
Inventors:
Randall T. Moon - Kenmore WA, US
Travis L. Biechele - Seattle WA, US
Nathan D. Camp - Seattle WA, US
Stephen Haggarty - Dorchester MA, US
Daniel Fass - Cambridge MA, US
Andy J. Chien - Bellevue WA, US
Assignee:
UNIVERSITY OG WASHINGTON - Seattle WA
MASSACHUSETTS INSTITUTE OF TECHNOLOGY - Cambridge MA
International Classification:
A61K 33/14
A61K 31/4965
A61P 35/00
US Classification:
424677, 51425504
Abstract:
The present invention is directed to a composition comprising a modulator of the Wnt/β-catenin pathway or a pharmaceutically acceptable salt thereof and an N-cinnamyl-N′-benzhydryl piperazine or a pharmaceutically acceptable salt thereof. The present invention is also directed to a method of treating a neoplastic condition in a subject by administering the modulator of the Wnt/βcatenin pathway or a pharmaceutically acceptable salt thereof and an N-cinnamyl-N′-benzhydryl piperazine or a pharmaceutically acceptable salt thereof to the subject under conditions effective to treat a neoplastic disorder.

Molecular Modulators Of The Wnt/Beta-Catenin Pathway

US Patent:
2011025, Oct 13, 2011
Filed:
Sep 16, 2009
Appl. No.:
13/119206
Inventors:
Randall T. Moon - Kenmore WA, US
Travis L. Biechele - Seattle WA, US
Nathan D. Camp - Seattle WA, US
Stephen Haggarty - Dorchester MA, US
Daniel Fass - Winchester MA, US
Assignee:
MASSACHUSETTS INSTITUTE OF TECHNOLOGY - Cambridge MA
UNIVERSITY OF WASHINGTON - Seattle WA
International Classification:
A61K 31/7048
A61K 31/663
A61K 31/4406
A61K 31/167
A61K 31/203
A61K 31/424
A61K 31/553
A61K 31/428
A61K 31/52
A61K 31/444
A61K 31/197
A61P 35/00
A61P 19/08
A61P 3/10
A61P 7/00
A61P 25/00
A61P 25/28
A61P 17/14
A61P 1/02
A61P 31/18
A61P 35/02
A61P 25/24
A61K 31/495
US Classification:
514 27, 51425504, 514108, 514357, 514575, 514559, 514375, 51421113, 514367, 5142633, 514334, 514564, 51426337
Abstract:
The present invention is directed toward a method of treating a subject for a condition mediated by aberrant Wnt/β-catenin signaling by selecting a subject with a condition mediated by aberrant Wnt/β-catenin signaling and administering to the selected subject at least one compound selected from the group consisting of those set forth in Table 1, Table 2, Table 3, and a pharmaceutically acceptable salt thereof. A method of similarly modulating the Wnt/β-catenin pathway in a subject is also discussed.

Molecular Inhibitors Of The Wnt/Beta-Catenin Pathway

US Patent:
2012004, Feb 16, 2012
Filed:
Dec 21, 2009
Appl. No.:
13/141442
Inventors:
Randall T. Moon - Kenmore WA, US
Travis L. Biechele - Seattle WA, US
Nathan D. Camp - Seattle WA, US
Stephen Haggarty - Dorchester MA, US
Daniel Fass - Winchester MA, US
Assignee:
MASSACHUSETTS INSTITUTE OF TECHNOLOGY - Cambridge MA
UNIVERSITY OF WASHINGTON - Seattle WA
International Classification:
A61K 38/12
A61K 31/695
A61K 31/12
A61P 43/00
A61K 31/122
A61K 31/517
A61K 31/7034
A61K 31/365
A61K 31/4375
US Classification:
514 211, 514450, 514 63, 514463, 514685, 514279, 514680, 5142664, 514 25
Abstract:
The present invention is directed toward a method of treating a subject for a condition mediated by the Wnt/β-catenin pathway by selecting a subject with a condition mediated by the Wnt/β-catenin pathway and administering to the selected subject a compound selected from the group consisting of those set forth in Table 1, Table 2, and a pharmaceutically acceptable salt thereof. A method of similarly inhibiting the Wnt/β-catenin pathway in a subject is also disclosed.

Molecular Activators Of The Wnt/Beta-Catenin Pathway

US Patent:
2012004, Feb 23, 2012
Filed:
Dec 21, 2009
Appl. No.:
13/141838
Inventors:
Randall T. Moon - Kenmore WA, US
Travis L. BIechele - Seattle WA, US
Nathan D. Camp - Seattle WA, US
Stephen Haggarty - Dorchester MA, US
Daniel Fass - Winchester MA, US
Assignee:
MASSACHUSETTS INSTITUTE OF TECHNOLOGY - Cambridge MA
UNIVERSITY OF WASHINGTON - Seattle WA
International Classification:
A61K 31/695
A61K 31/497
A61K 31/343
A61K 31/336
A61K 31/4402
A61K 31/015
A61K 31/553
A61K 31/55
A61K 31/4245
A61K 31/506
A61K 31/4406
A61K 31/167
A61K 31/4409
A61K 31/472
A61K 31/69
A61K 31/453
A61K 31/404
A61K 31/427
A61K 31/426
A61P 35/00
A61K 31/5377
US Classification:
514 63, 5142348, 51425212, 514468, 514475, 514277, 514763, 51421108, 51421206, 51421702, 514364, 514470, 514275, 514357, 514619, 514309, 5142352, 514 64, 514326, 514414, 514369
Abstract:
The present invention is directed toward a method of treating a subject for a condition mediated by aberrant Wnt/β-catenin signaling by selecting a subject with a condition mediated by aberrant Wnt/β-catenin signaling and administering to the selected subject a compound selected from the group consisting of those set forth in Table 1, Table 2, and a pharmaceutically acceptable salt thereof. A method of similarly modulating the Wnt/β-catenin pathway in a subject is also discussed.

Compositions Of Modulators Of The Wnt/Beta-Catenin Pathway And Benzamide And/Or Hydroxamic Acid Derivatives To Treat Bipolar Disorder

US Patent:
2013003, Feb 14, 2013
Filed:
Dec 23, 2009
Appl. No.:
13/141747
Inventors:
Daniel Fass - Winchester MA, US
Stephen Haggarty - Dorchester MA, US
Edward Scolnick - Wayland MA, US
Randall T. Moon - Kenmore WA, US
Travis L. Biechele - Seattle WA, US
Nathan D. Camp - Seattle WA, US
Assignee:
UNIVERSITY OF WASHINGTON - Seattle WA
MASSACHUSETTS INSTITUTE OF TECHNOLOGY - Cambridge MA
International Classification:
A61K 31/167
A61K 31/4406
A61P 25/00
A61K 31/513
A61K 33/14
A61K 33/00
A61K 31/4045
A61K 31/194
US Classification:
424677, 514616, 514415, 514357, 514574, 514274, 424715
Abstract:
The present invention is directed to a composition comprising a modulator of the Wnt/β-catenin pathway, such as a GSK-3 inhibitor, or a pharmaceutically acceptable salt thereof either with a benzamide derivative or a pharmaceutically acceptable salt thereof or with a hydroxamic acid or a pharmaceutically acceptable salt thereof. The present invention is also directed to a method of treating bipolar disorder in a subject by administering either a benzamide derivative or a hydroxamic acid to the subject under conditions effective to treat a bipolar disorder. A modulator of the Wnt/β-catenin pathway, such as a GSK-3 inhibitor, or a pharmaceutically acceptable salt thereof may also be administered to a subject.

Molecular Modulators Of The Wnt/Beta-Catenin Pathway

US Patent:
2014008, Mar 20, 2014
Filed:
Nov 18, 2013
Appl. No.:
14/082810
Inventors:
Stephen Haggarty - Dorchester MA, US
Daniel Fass - Cambridge MA, US
Assignee:
UNIVERSITY OF WASHINGTON - Seattle WA
The General Hospital Corporation - Boston MA
MASSACHUSETTS INSTITUTE OF TECHNOLOGY - Cambridge MA
International Classification:
A61K 31/428
A61K 31/495
A61K 31/4406
A61K 31/43
A61K 31/203
A61K 31/7048
A61K 31/424
A61K 31/553
A61K 31/663
A61K 31/167
US Classification:
514 27, 514367, 514108, 51425504, 514357, 514575, 514559, 514375, 51421113, 514197
Abstract:
The present invention is directed toward a method of treating a subject for a condition mediated by aberrant Wnt/β-catenin signaling by selecting a subject with a condition mediated by aberrant Wnt/β-catenin signaling and administering to the selected subject at least one compound selected from the group consisting of those set forth in Table 1, Table 2, Table 3, and a pharmaceutically acceptable salt thereof. A method of similarly modulating the Wnt/β-catenin pathway in a subject is also discussed.

Uses Of Chemicals To Modulate Gsk-3 Signaling For Treatment Of Bipolar Disorder And Other Brain Disorders

US Patent:
2011000, Jan 13, 2011
Filed:
Feb 27, 2010
Appl. No.:
12/660591
Inventors:
Stephen J. Haggarty - Dorchester MA, US
Daniel Fass - Winchester MA, US
Jennifer Pan - Acton MA, US
Josh Ketterman - Cambridge MA, US
Edward Holson - Newton Highlands MA, US
Tracey Lynn Petryshen - Cambridge MA, US
Michael C. Lewis - Boston MA, US
International Classification:
A61K 33/00
A61K 31/407
A61K 31/4545
A61K 31/404
A61K 31/553
A61K 31/506
A61P 25/00
US Classification:
424715, 424722, 514410, 514318, 514414, 51421108, 514275
Abstract:
Aspects of this invention are related, at least in part, to the use of chemical compounds able to inhibit GSK-3 and/or to stabilize β-catenin and formulations thereof. Some aspects of this invention relate to compositions comprising such compounds. Some aspects of the invention provide methods of using such compounds and/or compositions in the treatment of subjects having a neurological disease and/or psychiatric disorder. Some aspects of this invention provide methods of using ruboxistaurin, enzastaurin, sunitinib, midostaurin, lestaurtinib, 7-hydroxystaurosporine, and/or Chir99021 in the treatment of subjects having a neurological disease and/or psychiatric disorder. In some embodiments, compounds are administered in combination with Lithium.

Molecular Activators Of The Wnt/Beta-Catenin Pathway

US Patent:
2017004, Feb 23, 2017
Filed:
May 1, 2015
Appl. No.:
14/701936
Inventors:
Randall T. Moon - Kenmore WA, US
Travis L. Biechele - Seattle WA, US
Nathan D. Camp - Seattle WA, US
Stephen Haggarty - Dorchester MA, US
Daniel Fass - Winchester MA, US
Assignee:
THE GENERAL HOSPITAL CORPORATION - Boston MA
UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION - Seattle WA
MASSACHUSETTS INSTITUTE OF TECHNOLOGY - Cambridge MA
International Classification:
A61K 31/708
A61K 31/353
A61K 31/7048
A61K 31/357
A61K 31/506
A61K 31/4406
A61K 31/167
A61K 31/196
A61K 31/24
A61K 31/4409
A61K 31/472
A61K 31/5377
A61K 31/69
A61K 31/15
A61K 31/495
A61K 31/426
A61K 31/52
A61K 31/404
A61K 31/405
A61K 31/4178
A61K 31/4439
A61K 31/047
A61K 31/695
A61K 31/407
A61K 31/403
A61K 31/421
A61K 31/5383
A61K 31/351
A61K 31/4152
A61K 31/166
A61K 31/585
A61K 31/57
A61K 31/565
A61K 31/365
A61K 31/201
A61K 31/336
A61K 31/4402
A61K 31/015
A61K 31/366
A61K 31/553
A61K 31/5575
A61K 31/55
A61K 31/27
A61K 31/4245
A61K 31/352
Abstract:
The present invention is directed toward a method of treating a subject for a condition mediated by aberrant Wnt/β-catenin signaling by selecting a subject with a condition mediated by aberrant Wnt/β-catenin signaling and administering to the selected subject a compound selected from the group consisting of those set forth in Table 1, Table 2, and a pharmaceutically acceptable salt thereof. A method of similarly modulating the Wnt/β-catenin pathway in a subject is also discussed.

Possible Relatives

Eric S Fass  Grace A Fass  Joseph J Fass  Kenneth M Fass  Robert A Fass  Ronald G Fass  Susan R Fass  Daniel M Standish  Daniel K Standridge  Daniel C Stanfield 

NOTICE: You may not use PeopleBackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. PeopleBackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.